Literature DB >> 29126496

Chemotherapy for Oral Cancer.

Lee Hartner1.   

Abstract

The use of chemotherapy, including immunotherapy, in oral squamous cell carcinoma has expanded considerably in the past several years. Its use mirrors that in the treatment of squamous cell carcinoma affecting other structures in the head and neck. This article summarizes the current evidence that guides use of chemotherapy both in combination with radiation and as monotherapy for patients with advanced disease. It also addresses the expanding role of immunotherapy, particularly use of programmed cell death-ligand 1 inhibitors, in the treatment of advanced disease.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cetuximab; Chemoradiation; Chemotherapy; Cisplatin; Nivolumab; Oral cancer; Pembrolizumab

Mesh:

Substances:

Year:  2017        PMID: 29126496     DOI: 10.1016/j.cden.2017.08.006

Source DB:  PubMed          Journal:  Dent Clin North Am        ISSN: 0011-8532


  25 in total

1.  Discovery of a potent cytotoxic agent that promotes G2/M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line.

Authors:  Manunya Nuth; Manjunatha R Benakanakere; Robert P Ricciardi
Journal:  Int J Oncol       Date:  2022-02-25       Impact factor: 5.650

Review 2.  The Microenvironment of Tongue Cancer.

Authors:  Want Tao; Zeng Li-Juan; Li Kan; Li Jing-Yuan; Liu Xiang-Qi; Liang Yu-Jie
Journal:  Adv Exp Med Biol       Date:  2020       Impact factor: 2.622

Review 3.  Genetic alterations and clinical dimensions of oral cancer: a review.

Authors:  Keerthana Karunakaran; Rajiniraja Muniyan
Journal:  Mol Biol Rep       Date:  2020-10-21       Impact factor: 2.316

4.  Prognostic factors on surgically and non-surgically treated oral squamous cell carcinoma: Advances in survival in fifteen years of follow up.

Authors:  Paulo-Goberlânio-de Barros Silva; José-Vitor-Mota Lemos; Marcela-Maria-Fontes Borges; Talita-Jordânia-Rocha do Rêgo; Thinali-Sousa Dantas; Carlos-Heli-Bezerra Leite; Marcos-Venício-Alves Lima; Maria-do Perpétuo-Socorro-Saldanha Cunha; Fabrício-Bitu Sousa
Journal:  J Clin Exp Dent       Date:  2021-03-01

5.  ANLN promotes carcinogenesis in oral cancer by regulating the PI3K/mTOR signaling pathway.

Authors:  Bing Wang; Xiao-Li Zhang; Chen-Xi Li; Ning-Ning Liu; Min Hu; Zhong-Cheng Gong
Journal:  Head Face Med       Date:  2021-06-03       Impact factor: 2.151

6.  Mitochondrial Stress-Mediated Targeting of Quiescent Cancer Stem Cells in Oral Squamous Cell Carcinoma.

Authors:  Tajindra Singh Saluja; Vijay Kumar; Monika Agrawal; Abhilasha Tripathi; Rajesh Kumar Meher; Kamini Srivastava; Anurag Gupta; Anjana Singh; Arun Chaturvedi; Satyendra Kumar Singh
Journal:  Cancer Manag Res       Date:  2020-06-15       Impact factor: 3.989

7.  Cancer cell membrane-coated mesoporous silica loaded with superparamagnetic ferroferric oxide and Paclitaxel for the combination of Chemo/Magnetocaloric therapy on MDA-MB-231 cells.

Authors:  Defu Cai; Likun Liu; Cuiyan Han; Xiaoxing Ma; Jiayi Qian; Jianwen Zhou; Wenquan Zhu
Journal:  Sci Rep       Date:  2019-10-09       Impact factor: 4.379

8.  Oxidative Stress-Dependent Synergistic Antiproliferation, Apoptosis, and DNA Damage of Ultraviolet-C and Coral-Derived Sinularin Combined Treatment for Oral Cancer Cells.

Authors:  Sheng-Yao Peng; Jen-Yang Tang; Ruei-Nian Li; Hurng-Wern Huang; Chang-Yi Wu; Chien-Chih Chiu; Fang-Rong Chang; Hong-Wei Zhang; Yun-Jou Lee; Jyh-Horng Sheu; Hsueh-Wei Chang
Journal:  Cancers (Basel)       Date:  2021-05-18       Impact factor: 6.639

9.  Differential expression of ghrelin and GHSR via the mTOR pathway during the dynamic carcinogenic process involving oral, potentially malignant disorders.

Authors:  Jianing Lou; Lin Liu; Weizhen Zhang; Zengtong Zhou; Yuan Fan
Journal:  Biosci Rep       Date:  2019-12-20       Impact factor: 3.840

10.  Traditional Chinese medicine for oral squamous cell carcinoma: A Bayesian network meta-analysis protocol.

Authors:  Dong Wang; XiaoJie Duan; Yuhui Zhang; Zhen Meng; Jing Wang
Journal:  Medicine (Baltimore)       Date:  2020-10-23       Impact factor: 1.817

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.